Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Childs

Showing results (131-140 of 151) with videos related to

Pageof 16
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial CohortsJack R Andrews, Yohan Kim, Edlira Horjeti, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 21, 2025
[<sup>177</sup>Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastasesGokce Belge Bilgin, Cem Bilgin, Brian J Burkett, et al.
European Urology Oncology|August 2, 2025
Outcomes for [<sup>177</sup>Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate CancerMiguel Muniz, Oliver Sartor, Jacob J Orme, et al.
Cancers|June 19, 2024
Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic StrategiesAhmed M Mahmoud, Amr Moustafa, Carter Day, et al.
Cancer Treatment Reviews|May 4, 2024
Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are goingMiguel Muniz, Charles L Loprinzi, Jacob J Orme, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Safety and immunogenicity of a tri-antigen vaccine targeting IGFBP-2, HER2, and IGF-IR in participants with non-metastatic breast cancerSasha E Stanton, Denise L Cecil, Howard H Bailey, et al.
Nature Genetics|November 7, 1998
A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasisS S Strautnieks, L N Bull, A S Knisely, et al.
Clinical and Translational Radiation Oncology|April 24, 2026
Outcomes of stereotactic body radiotherapy for supraclavicular lymph node metastasis among patients with metastatic prostate cancerAndres L Frias, Bradley J Stish, Ryan M Phillips, et al.
Journal of Pain and Symptom Management|May 5, 2025
Olanzapine for Managing Side Effects From Antiangiogenic Tyrosine-Kinase InhibitorsRegina M Koch, Miguel Muniz, Candy S Peskey, et al.
Journal for Immunotherapy of Cancer|September 17, 2021
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlatesJohn B Liao, William R Gwin, Renata R Urban, et al.
Pageof 16

Showing results (131-140 of 151) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial CohortsJack R Andrews, Yohan Kim, Edlira Horjeti, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 21, 2025
[<sup>177</sup>Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastasesGokce Belge Bilgin, Cem Bilgin, Brian J Burkett, et al.
European Urology Oncology|August 2, 2025
Outcomes for [<sup>177</sup>Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate CancerMiguel Muniz, Oliver Sartor, Jacob J Orme, et al.
Cancers|June 19, 2024
Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic StrategiesAhmed M Mahmoud, Amr Moustafa, Carter Day, et al.
Cancer Treatment Reviews|May 4, 2024
Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are goingMiguel Muniz, Charles L Loprinzi, Jacob J Orme, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Safety and immunogenicity of a tri-antigen vaccine targeting IGFBP-2, HER2, and IGF-IR in participants with non-metastatic breast cancerSasha E Stanton, Denise L Cecil, Howard H Bailey, et al.
Nature Genetics|November 7, 1998
A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasisS S Strautnieks, L N Bull, A S Knisely, et al.
Clinical and Translational Radiation Oncology|April 24, 2026
Outcomes of stereotactic body radiotherapy for supraclavicular lymph node metastasis among patients with metastatic prostate cancerAndres L Frias, Bradley J Stish, Ryan M Phillips, et al.
Journal of Pain and Symptom Management|May 5, 2025
Olanzapine for Managing Side Effects From Antiangiogenic Tyrosine-Kinase InhibitorsRegina M Koch, Miguel Muniz, Candy S Peskey, et al.
Journal for Immunotherapy of Cancer|September 17, 2021
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlatesJohn B Liao, William R Gwin, Renata R Urban, et al.
Pageof 16